Qubo Open the TerminalOpen the Terminal

$ cd /reports / pharma-biotech

Sector overviewQ4 202626 slides

Pharma & biotech

Obesity drugs are driving record growth: Lilly’s Q3 revenue rose 39%, with volume up 53% even as realised prices fell 15%. Around $300B of industry revenue loses patent protection by 2030, which is pushing companies into M&A ($130B in H1 2026 alone). Washington now effectively sets prices: 26 drugmakers have signed most-favoured-nation pricing deals, and the rest face 100% tariffs on patented imports. Biotech is recovering, with the XBI index up 27% year to date and the IPO window open again.

Published 22 Oct 2026Pharma & biotech PHARMA-BIOTECHNext edition 1 Jan

SLIDE 01 / 26Cover of the Pharma & biotech report

The first slides, as they appear in the reader.

How to read it.

Starter

Not included

Qubo Research is for subscribers, from Pulse.

Pulse · Edge

Apex only

Sector overviews and ideas are part of the Apex library.

Apex

Library included

Every report, every edition and the archives. 5 custom reports a month.

Editions:Q4 2026Follow the series in the Terminal to get the next one.

Read it next to the live PHARMA-BIOTECH chart.

Open the report in the Terminal: price, news and why it moves, on the same screen.

Open the TerminalOpen the Terminal

General research, the same for every reader: it does not take anyone’s situation into account and does not recommend buying, selling or holding any asset. No price targets. May contain errors.